Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.
P/E ratio for Ampio Pharmaceuticals, Inc. (AMPE)
P/E ratio as of 2023: -0.19
According to Ampio Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.19. At the end of 2022 the company had a P/E ratio of -0.41.
P/E ratio history for Ampio Pharmaceuticals, Inc. from 2006 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.19 |
| 2022 | -0.41 |
| 2021 | -9.10 |
| 2020 | -16.66 |
| 2019 | -9.50 |
| 2018 | 1.27 |
| 2017 | -5.11 |
| 2016 | -2.52 |
| 2015 | -5.68 |
| 2014 | -4.52 |
| 2013 | -11.37 |
| 2012 | -10.52 |
| 2011 | -6.05 |
| 2010 | -5.24 |
| 2009 | -1987.47 |
| 2008 | -2041.34 |
| 2007 | -2034.07 |
| 2006 | -64819.72 |